The acute myeloid leukemia (AML) treatment landscape has changed substantially since
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute
myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a …

Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for
patients with AML was limited to induction chemotherapy with cytarabine and anthracycline …

Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017.
This is due to the US Food and Drug Administration's approval of several new, targeted …

The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for
the past four decades. Improvements in supportive care and modifications to the dose and …

More than one quarter of a million adults throughout the world are diagnosed annually with
acute myeloid leukemia (AML). Despite considerable progress during the past 3 decades in …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …